Market Cap 326.55B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 18.07
Forward PE 15.11
Profit Margin 7.59%
Debt to Equity Ratio 19.96
Volume 7,806,300
Avg Vol 8,300,596
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 17%
Beta 0.56
Analysts Strong Sell
Price Target $210.04

Latest News on ABBV

Best Dividend Aristocrats For May 2025

Apr 29, 2025, 8:07 PM EDT - 11 days ago

Best Dividend Aristocrats For May 2025

ABT ADM ADP AFL ALB AMCR AOS


Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results

Apr 27, 2025, 11:40 PM EDT - 13 days ago

Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results


AbbVie's First Quarter Beat And Raise Leaves Room For More

Apr 25, 2025, 5:17 PM EDT - 16 days ago

AbbVie's First Quarter Beat And Raise Leaves Room For More


AbbVie: Q1 Earnings Reinforce Positive Momentum

Apr 25, 2025, 4:00 PM EDT - 16 days ago

AbbVie: Q1 Earnings Reinforce Positive Momentum


AbbVie Inc. (ABBV) Q1 2025 Earnings Call Transcript

Apr 25, 2025, 12:14 PM EDT - 16 days ago

AbbVie Inc. (ABBV) Q1 2025 Earnings Call Transcript


AbbVie Reports First-Quarter 2025 Financial Results

Apr 25, 2025, 7:43 AM EDT - 16 days ago

AbbVie Reports First-Quarter 2025 Financial Results


Final Trades: TJX, Meta, Abbvie and Taiwan Semi

Apr 11, 2025, 2:06 PM EDT - 4 weeks ago

Final Trades: TJX, Meta, Abbvie and Taiwan Semi

META TJX TSM


AbbVie Stock Up 9.2% After Key Signal

Apr 10, 2025, 7:43 AM EDT - 4 weeks ago

AbbVie Stock Up 9.2% After Key Signal


AbbVie: Thriving Beyond Humira's Patent Cliff (Upgrade)

Apr 9, 2025, 5:29 PM EDT - 4 weeks ago

AbbVie: Thriving Beyond Humira's Patent Cliff (Upgrade)